VICTORIA (hormone receptor postiVe endometrIal Carcinoma treated by dual mTORC1/mTORC2 Inhibitor and Anastrozole):A Multicentric, randomized, non comparative, open-label Phase I/II evaluating AZD2014 (dual mTORC1/mTORC2 inhibitor) in combination with anastrozole versus anastrozole alone in the treatment of metastatic hormone receptor-positive endometrial adenocarcinoma

2024-516725-31-00 Protocol ET-15-036 Phase I and Phase II (Integrated) - Other Ongoing, recruiting

Start 14 Apr 2016 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol ET-15-036

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruiting
Participants planned 72
Countries 1
Sites 4

advanced and metastatic

Key facts

Sponsor
Centre Leon Berard
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
14 Apr 2016 → ongoing
Decision date (initial)
2024-11-27
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516725-31-00
EudraCT number
2015-002412-32

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

advanced and metastatic

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Leon Berard

Sponsor organisation
Centre Leon Berard
Address
28 Rue Laennec
City
Lyon
Postcode
69008
Country
France

Scientific contact point

Organisation
Centre Leon Berard
Contact name
Pierre Etienne HEUDEL

Public contact point

Organisation
Centre Leon Berard
Contact name
Project Manager

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 72 4
Rest of world 0

Investigational sites

France

4 sites · Ongoing, recruiting
Centre Oscar Lambret
Medical Oncology, 3 Rue Frederic Combemale, 59000, Lille
Institut De Cancerologie De L Ouest
Medical Oncology, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Institut Bergonie
Medical Oncology, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
CHU Besancon
Medical Oncology, 3 Boulevard Alexander Fleming, Cs 81816, Besancon Cedex

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2016-04-14 2016-04-14

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-14 France Acceptable
2024-11-22
2024-11-27